FDA Panel Gives Emergency Approval to Moderna COVID-19 Vaccine

An independent advisory committee to the United States Food and Drug Administration (FDA) has recommended the COVID-19 vaccine developed by Moderna and the National Institute of Allergy and Infectious Diseases (NIAID).

An independent advisory committee to the United States Food and Drug Administration (FDA) has recommended the COVID-19 vaccine developed by Moderna and the National Institute of Allergy and Infectious Diseases (NIAID).

The Vaccines and Biological Products Advisory Committee voted 20 to 0 for the approval of the second COVID-19 vaccine in the U.S. last Dec. 17, a week after the committee recommended the vaccine developed by Pfizer and BioNTech for emergency use authorization (EUA).

The committee recommended the Moderna vaccine for people aged 18 and above, unlike with the Pfizer-BioNTech vaccine that was recommended for people as young as 16. Healthcare workers and nursing home residents continue to be the priority for receiving the vaccine.

Gen. Gustave Perna, the chief officer of Operation Warp Speed, said at a press briefing last Dec. 14 that the U.S. plans to order six million doses of the Moderna vaccine, more than double the amount of the initial shipment of the Pfizer-BioNTech vaccine, with the first shots administered last Dec. 14 after the FDA granted it EUA.

The recommendation comes as the FDA is updating the guidelines for doctors after two Alaskan healthcare workers experienced allergic reactions to the Pfizer-BioNTech vaccine.

According to the FDA, the most common side effects from the Moderna vaccine include muscle pain, headache, and fatigue.

In a trial of over 30,000 participants, FDA found out that the Moderna vaccine is more than 94% effective at preventing COVID-19.


© Fourth Estate® — All Rights Reserved.
This material may not be published, broadcast, rewritten or redistributed.